SOUTH SAN FRANCISCO, Calif. and GENEVA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and Antion Biosciences, a Swiss cell and gene engineering company, today announced that they have entered into an exclusive collaboration and global license agreement for Antion’s miRNA technology (miCAR™) to advance multiplex gene silencing as an additional tool to develop next generation allogeneic CAR T products.
Read more at globenewswire.comAllogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.